

SEP - 8 2004



K041872  
page 1 of 1

## 510(k) Summary

**Applicant/Sponsor:** Biomet, Inc.

**Contact Person:** Patricia Sandborn Beres  
Senior Regulatory Specialist

**Proprietary Name:**

- 1) Ascent™ Porous Open Box PS Component
- 2) Ascent™ Posterior Stabilized (PS) Distal Femoral Pegs

**Common Name:** Ascent™ Knee System

**Classification Name:** Knee joint patellofemorotibial metal/polymer porous coated uncemented (21 CFR 888.3565)

**Legally Marketed Devices To Which Substantial Equivalence Is Claimed:** Ascent™ Porous Open Box PS Femoral Component (K002678) and Biomet Non-Cement (K033489).

**Device Description:** The Ascent™ Porous Open Box PS Femoral Component is a metallic knee femoral component to be used with Biomet's Ascent™ tibial base-plate components. The device also includes distal femoral pegs. The modular pegs are designed to fasten into the existing distal augment holes of the femoral component and act as alignment devices. The device is manufactured of CoCrMo Alloy and is intended for non-cemented use. The components are identical to those cleared in the previous 510(k) submission (K002678) for cemented application.

**Intended Use:** Non-cemented total knee replacement

**Indications for Use:** The indications for Biomet's Ascent™ Porous Open Box PS Femoral Component include:

1. Painful and disabled knee joint resulting from osteoarthritis, rheumatoid arthritis, traumatic arthritis, where one or more compartments are involved.
2. Correction of varus, valgus or posttraumatic deformity
3. Correction of revision of unsuccessful osteotomy, arthrodesis, or failure of previous joint replacement procedure.

**Summary of Technologies:** The device to be covered by this 510(k) is identical to devices covered by previously cleared 510(k) submissions for cemented application.

**Clinical and Non-Clinical Testing:** None provided

*All trademarks are property of Biomet, Inc*

MAILING ADDRESS  
P.O. Box 587  
Warsaw, IN 46581-0587

SHIPPING ADDRESS  
56 E. Bell Drive  
Warsaw, IN 46582

OFFICE  
574.267.6639

FAX  
574.267.8157

E-MAIL  
biomet@biomet.com



SEP - 8 2004

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

Ms. Patricia Sandborn Beres  
Senior Regulatory Specialist  
Biomet Manufacturing Corporation  
P.O. Box 587  
Warsaw, Indiana 46581-0587

Re: K041872

Trade/Device Name: Ascent™ Porous Open Box PS Femoral Component

Regulation Number: 21 CFR 888.3565

Regulation Name: Knee joint patellofemorotibial metal/polymer porous-coated uncemented prosthesis.

Regulatory Class: II

Product Code: MBH

Dated: July 8, 2004

Received: June 9, 2004

Dear Ms. Beres:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set

forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4659. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>

Sincerely yours,

A handwritten signature in black ink, appearing to read "Celia M. Witten". The signature is fluid and cursive, with a long horizontal stroke at the end.

Celia M. Witten, Ph.D., M.D.  
Director  
Division of General, Restorative and  
Neurological Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

## Indications for Use

510(k) Number (if known): K041872

Device Name: Ascent™ Porous Open Box PS Femoral Component

Indications For Use:

- 1) Painful and disabled knee joint resulting from osteoarthritis, rheumatoid arthritis, traumatic arthritis, where one or more compartments are involved.
- 2) Correction of varus, valgus or posttraumatic deformity
- 3) Correction of revision of unsuccessful osteotomy, arthrodesis, or failure of previous joint replacement procedure.

Prescription Use X  
(Part 21 CFR 801 Subpart D)


AND/OR

Over-The-Counter Use \_\_\_\_\_  
(21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

---

Concurrence of CDRH, Office of Device Evaluation (ODE)

  
**(Division Sign-Off)**  
**Division of General, Restorative,  
and Neurological Devices**

Page 1 of X

**510(k) Number** K041872